PureTech Health (NASDAQ:PRTC) Shares Gap Down – What’s Next?

PureTech Health plc (NASDAQ:PRTC)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $22.56, but opened at $22.05. PureTech Health shares last traded at $22.05, with a volume of 361 shares trading hands.

Analysts Set New Price Targets

Several brokerages have issued reports on PRTC. Leerink Partners began coverage on PureTech Health in a report on Monday, September 9th. They issued an “outperform” rating and a $45.00 price target on the stock. Leerink Partnrs upgraded PureTech Health to a “strong-buy” rating in a report on Monday, September 9th.

PureTech Health Trading Down 3.4 %

The firm’s 50-day moving average price is $21.18 and its 200 day moving average price is $22.71.

Institutional Trading of PureTech Health

An institutional investor recently bought a new position in PureTech Health stock. Birch Hill Investment Advisors LLC bought a new stake in shares of PureTech Health plc (NASDAQ:PRTC) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned about 1.26% of PureTech Health as of its most recent SEC filing. 0.04% of the stock is owned by institutional investors and hedge funds.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.